Food and Drug Administration

Exercise as a Novel Treatment for Drug Addiction: A Neurobiological and Stage-Dependent Hypothesis.

Exercise as a novel treatment for drug addiction: A neurobiological and stage-dependent hypothesis.

Neurosci Biobehav Rev. 2013 Jun 24;
Lynch WJ, Peterson AB, Sanchez V, Abel J, Smith MA

Physical activity, and specifically exercise, has been suggested as a… Continue reading →

Long-Acting Nifedipine for Hypertensive Patients in the Middle East and Morocco: Observations on Efficacy and Tolerability of Monotherapy or Combination Therapy.

Long-acting nifedipine for hypertensive patients in the Middle East and Morocco: observations on efficacy and tolerability of monotherapy or combination therapy.

Integr Blood Press Control. 2013; 6: 49-57
Ghoneim RA, Omar AK, Sebastian V, Kassab R, Akijian G, Hafiz… Continue reading →

Insulin Degludec: A Long-Acting Modern Insulin Analogue With a Predictable Pharmacokinetic/pharmacodynamic Profile.

Insulin degludec: a long-acting modern insulin analogue with a predictable pharmacokinetic/pharmacodynamic profile.

Drugs Today (Barc). 2013 Jun; 49(6): 387-397
Rendell M

Insulin degludec is, like insulin detemir, a product of coupling of Des-B30 threonine insulin to fatty acid side… Continue reading →

Managing Hepatitis C in Users of Illicit Drugs.

Managing Hepatitis C in Users of Illicit Drugs.

Curr Hepat Rep. 2007; 6(2): 60-67
Edlin BR, Carden MR, Ferrando SJ

Persons who inject illicit drugs are the group most severely affected by the hepatitis C epidemic but the least… Continue reading →

[Vemurafenib (Zelboraf) in the Therapy of Melanoma].

[Vemurafenib (Zelboraf) in the therapy of melanoma].

Magy Onkol. 2013 Jun; 57(2): 110-3
Liszkay G

The incidence of malignant melanoma is continuously rising, but the therapy of advanced melanoma remains insufficient. Advances in the understanding of the immunological and… Continue reading →

Update on the Safety and Bioequivalence of Biosimilars – Focus on Enoxaparin.

Update on the safety and bioequivalence of biosimilars – focus on enoxaparin.

Drug Healthc Patient Saf. 2013; 5: 133-141
Jeske W, Walenga JM, Hoppensteadt D, Fareed J

Generic forms of chemically-derived drugs must exhibit chemical identity and be bioequivalent… Continue reading →

Preliminarily Analysis of Carbamazepine (CBZ) C0 in Patients Visited Isfahan Epileptic Clinics.

Preliminarily Analysis of Carbamazepine (CBZ) C0 in Patients Visited Isfahan Epileptic Clinics.

Int J Prev Med. 2013 May; 4(Suppl 2): S343-6
Tolou-Ghamari Z, Najafi MR, Habibabadi JM, Zare M

Carbamazepine (CBZ) is mostly considered as the first line of… Continue reading →

Iron Deficiency Anemia in Patients With Inflammatory Bowel Disease.

Iron deficiency anemia in patients with inflammatory bowel disease.

Clin Exp Gastroenterol. 2013; 6: 61-70
Goldberg ND

Iron deficiency anemia is the most common form of anemia worldwide, caused by poor iron intake, chronic blood loss, or impaired absorption.… Continue reading →

Pluripotent Stem Cells in Translation: A Food and Drug Administration-National Institutes of Health Collaboration.

Pluripotent Stem Cells in Translation: A Food and Drug Administration-National Institutes of Health Collaboration.

Stem Cells Transl Med. 2013 Jun 11;
Kleitman N, Rao MS, Owens DF

Recently, the U.S. Food and Drug Administration (FDA), the U.S. National Institutes… Continue reading →

Characterizing Protein Domain Associations by Small-Molecule Ligand Binding.

Characterizing protein domain associations by Small-molecule ligand binding.

J Proteome Sci Comput Biol. 2012 Dec 3; 1:
Li Q, Cheng T, Wang Y, Bryant SH

Protein domains are evolutionarily conserved building blocks for protein structure and function, which are… Continue reading →